The global microarray analysis market was valued at USD 1.88 billion in 2025. The market is estimated at USD 1.92 billion in 2026 and is projected to reach USD 2.58 billion by 2036, at a CAGR of 3.0% during the forecast period 2026-2036. This report provides a detailed assessment of the market, covering array formats and content, imputation, microarrays versus sequencing, technology substitution by application, installed base, regulation and reimbursement, cost per sample, the supplier landscape, and growth opportunities.
The market covers the consumables, instruments, software, and services used to analyze many biological targets in parallel on probes fixed in an ordered pattern on a solid surface. It includes DNA microarrays for genotyping, copy number, methylation, and expression analysis, protein and antibody arrays used to screen biomarkers and autoantibodies, tissue and cell arrays for pathology research, and other formats such as carbohydrate and small-molecule arrays. Arrays and reagents make up most recurring spending, alongside scanners, hybridization and wash stations, automation systems, analysis software, and genotyping and profiling services. Sequencing products, bead-based immunoassays, spatial transcriptomics, sample preparation products, and clinical test revenue from array-based tests are excluded.
The microarray analysis market is a mature one, as next-generation sequencing has taken over gene expression profiling and most discovery research, and demand now rests on uses where arrays keep a clear cost or reimbursement edge. Illumina reported second-quarter 2026 microarrays and other revenue of USD 105 million, compared with sequencing consumables revenue of USD 775 million, and that revenue line was down 4% on a rest-of-world organic basis. Population genotyping remains strong, as the U.K. program Our Future Health has run arrays on 755,000 of its more than 2.02 million recruits, measuring 686,416 variants and imputing 159,587,100 from them.
Continued displacement by sequencing is the main restraint, because sequencing needs no predefined probes and can detect novel and rare variants, and it is now standard in expression profiling and variant discovery. Arrays report only the positions they were designed to test, so rare variants, most insertions and deletions, and balanced rearrangements go undetected, and a negative result cannot rule out a genetic cause. The most serious long-term challenge is low-pass whole-genome sequencing with imputation, which could remove the main economic case for arrays in population genotyping if it reaches cost parity. The market also depends on payer policies that are reviewed periodically, and supplier consolidation has turned arrays into a minor product line at large companies focused on sequencing.
Array content designed for diverse ancestries and pharmacogenomics is a key opportunity, as arrays built mainly on European reference data perform less well elsewhere; Thermo Fisher Scientific, for example, has added biobank-oriented Axiom arrays and the PangenomiX array for diverse populations. New national cohort programs in Asia-Pacific and the Middle East, where budgets are tighter, favor array genotyping, and agrigenomics can expand into small ruminants, aquaculture, companion animals, crops, and livestock sectors in Asia, Latin America, and Africa. Arrays also fit as a low-cost first-tier test with sequencing kept for unresolved cases. Key trends include the concentration of array value in genotyping over expression, positioning arrays as complementary to sequencing, and content built for diverse populations and polygenic applications.
By product, the microarray analysis market is segmented into consumables (arrays & chips and reagents & kits), instruments (scanners & imaging systems and hybridization, washing & automation systems), and software & services. Consumables are expected to hold the largest share in 2026, because an array is used for every sample processed, a large installed base of array instruments operates in cytogenetics, agricultural, and biobank laboratories, and spending is concentrated in high-volume genotyping where consumable cost per sample drives purchasing. Software & services are expected to grow at the highest CAGR from a small base, as breeding organizations and cohort programs without their own laboratories outsource array genotyping, and analysis, imputation, and interpretation support now make up more of the value delivered as array hardware has become commoditized. Instrument sales are expected to grow slowly, since most demand is served by the existing installed base.
By type, the microarray analysis market is segmented into DNA microarrays (genotyping, copy number & cytogenetic, methylation, and expression arrays), protein & antibody microarrays, tissue & cell microarrays, and other microarrays such as carbohydrate arrays. In 2026, DNA microarrays are expected to hold the largest share and also to grow at the highest CAGR, as most remaining demand comes from cohort, farm, and drug-response genotyping and from copy number testing, the uses where arrays keep either a clear cost advantage or a reimbursed clinical role. Protein & antibody microarrays should grow modestly on autoantibody profiling, biomarker screening, and immune response work, while facing competition from multiplexed bead-based and proximity-based proteomic platforms. Tissue & cell microarrays are expected to grow slowly, keeping a role in pathology research and antibody validation as spatial profiling methods take on questions tissue arrays cannot answer.
By application, the microarray analysis market is segmented into genotyping (population & biobank, pharmacogenomic, and polygenic risk), cytogenetics & copy number analysis (CNV), gene expression profiling, agrigenomics & animal breeding, proteomic & biomarker profiling, and other applications. In 2026, genotyping is expected to hold the largest share and also to grow at the highest CAGR, supported by the economics of array genotyping with imputation in large cohorts, the launch of national cohort programs outside established markets, and the fit of arrays with pharmacogenomic and polygenic uses. Cytogenetics & copy number analysis should keep a large, steady share, as payers continue to cover chromosomal microarray testing for prenatal and pediatric cases. Agrigenomics should grow steadily, while gene expression profiling is expected to decline as RNA sequencing continues to replace expression arrays.
By end user, the microarray analysis market is segmented into academic & research institutes, biobanks & population genomics programs, clinical & diagnostic laboratories, agricultural & animal breeding organizations, and pharma & biotech companies. Clinical & diagnostic laboratories are expected to hold the largest share in 2026, given the high volume of chromosomal microarray tests in prenatal, pediatric, and cancer genetics, payer reimbursement for these tests, and the validated array platforms already in place in cytogenetics labs. Biobanks & population genomics programs are expected to grow at the highest CAGR, as established programs keep recruiting and genotyping participants, new national programs are starting in Asia-Pacific and the Middle East, and array genotyping with imputation remains far cheaper at this scale.
In 2026, North America is expected to hold the largest share of the microarray analysis market, supported by the volume of chromosomal microarray analysis performed under established coverage policies, large-scale genotyping in dairy, beef, swine, and poultry breeding, strong research activity, and the home base of leading suppliers Illumina, Thermo Fisher Scientific, and Agilent Technologies. Europe holds a significant share, backed by large biobank and cohort programs that genotype at scale, established clinical cytogenetics services, and breeding organizations using genomic selection. With programs such as the U.K.'s Our Future Health, the region is among the heaviest users of population arrays relative to its size.
Asia-Pacific is expected to grow at the highest CAGR during the forecast period, driven by national genomics initiatives across China, Japan, India, and Southeast Asia where arrays are the cost-effective choice at that scale, growing livestock and crop genotyping as farm production intensifies, rising clinical cytogenetics capacity, and the arrival of array content designed for non-European ancestries. Latin America and the Middle East & Africa hold smaller shares. Latin American demand comes mainly from cattle and poultry genotyping in Brazil and Argentina, while in the Middle East, national genome programs and clinical genetics capacity in Gulf countries, where consanguinity-related conditions are common, are expected to support growth.
The microarray analysis market is concentrated, with two suppliers, Illumina and Thermo Fisher Scientific, providing most genotyping and expression array capacity, and the rest of the market split among cytogenetics array suppliers such as Agilent Technologies, protein and tissue array specialists such as RayBiotech and Sengenics, and genotyping service providers such as Eurofins Scientific. For the largest players, arrays are now a minor business next to much larger sequencing operations. Key purchase factors are cost per sample, content and ancestry coverage, data quality, and imputation support. Most activity centers on content instead of new platforms, such as arrays for multi-ancestry cohorts, drug-response and polygenic panels, and additional farm species. According to Neogen, which announced the deal in March 2026, it is selling its GeneSeek genomics business, including the Igenity and GGP livestock genotyping portfolios, to Zoetis for USD 160 million.
Key companies profiled in the report include Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Revvity, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Zoetis Inc. (GeneSeek) (U.S.), Eurofins Scientific SE (Luxembourg), RayBiotech Life, Inc. (U.S.), Sengenics Corporation LLC (Singapore), and Merck KGaA (Germany).
The market covers the consumables, instruments, software, and services used to analyze many biological targets in parallel on probes fixed in an ordered pattern on a solid surface. It includes DNA microarrays for genotyping, copy number, methylation, and expression analysis, protein and antibody arrays used to screen biomarkers and autoantibodies, tissue and cell arrays for pathology research, and other formats such as carbohydrate and small-molecule arrays. Arrays and reagents make up most recurring spending, alongside scanners, hybridization and wash stations, automation systems, analysis software, and genotyping and profiling services. Sequencing products, bead-based immunoassays, spatial transcriptomics, sample preparation products, and clinical test revenue from array-based tests are excluded.
The microarray analysis market is a mature one, as next-generation sequencing has taken over gene expression profiling and most discovery research, and demand now rests on uses where arrays keep a clear cost or reimbursement edge. Illumina reported second-quarter 2026 microarrays and other revenue of USD 105 million, compared with sequencing consumables revenue of USD 775 million, and that revenue line was down 4% on a rest-of-world organic basis. Population genotyping remains strong, as the U.K. program Our Future Health has run arrays on 755,000 of its more than 2.02 million recruits, measuring 686,416 variants and imputing 159,587,100 from them.
Market Dynamics
Demand in the microarray analysis market is sustained first by the cost advantage of arrays in population-scale genotyping, where measuring a few hundred thousand known variants and imputing the rest costs a small fraction of sequencing, allowing cohort programs to genotype many more participants for the same budget. Livestock and crop breeding programs genotype very large numbers of animals and plants for breeding values, parentage, and trait screening, which calls for low cost per sample on known markers. Chromosomal microarray analysis holds a reimbursed position in prenatal and pediatric cytogenetics, and a payer medical policy revised in March 2026 covers it for several prenatal indications while declining to cover routine genome or exome sequencing for prenatal diagnosis outside clinical trials. Pharmacogenomic and polygenic risk genotyping add further demand, since both rely on defined sets of common variants.Continued displacement by sequencing is the main restraint, because sequencing needs no predefined probes and can detect novel and rare variants, and it is now standard in expression profiling and variant discovery. Arrays report only the positions they were designed to test, so rare variants, most insertions and deletions, and balanced rearrangements go undetected, and a negative result cannot rule out a genetic cause. The most serious long-term challenge is low-pass whole-genome sequencing with imputation, which could remove the main economic case for arrays in population genotyping if it reaches cost parity. The market also depends on payer policies that are reviewed periodically, and supplier consolidation has turned arrays into a minor product line at large companies focused on sequencing.
Array content designed for diverse ancestries and pharmacogenomics is a key opportunity, as arrays built mainly on European reference data perform less well elsewhere; Thermo Fisher Scientific, for example, has added biobank-oriented Axiom arrays and the PangenomiX array for diverse populations. New national cohort programs in Asia-Pacific and the Middle East, where budgets are tighter, favor array genotyping, and agrigenomics can expand into small ruminants, aquaculture, companion animals, crops, and livestock sectors in Asia, Latin America, and Africa. Arrays also fit as a low-cost first-tier test with sequencing kept for unresolved cases. Key trends include the concentration of array value in genotyping over expression, positioning arrays as complementary to sequencing, and content built for diverse populations and polygenic applications.
Segment Analysis
The report analyzes the market by product, type, application, end user, and geography, helping stakeholders identify the most attractive areas for product development, investment, and partnering.By product, the microarray analysis market is segmented into consumables (arrays & chips and reagents & kits), instruments (scanners & imaging systems and hybridization, washing & automation systems), and software & services. Consumables are expected to hold the largest share in 2026, because an array is used for every sample processed, a large installed base of array instruments operates in cytogenetics, agricultural, and biobank laboratories, and spending is concentrated in high-volume genotyping where consumable cost per sample drives purchasing. Software & services are expected to grow at the highest CAGR from a small base, as breeding organizations and cohort programs without their own laboratories outsource array genotyping, and analysis, imputation, and interpretation support now make up more of the value delivered as array hardware has become commoditized. Instrument sales are expected to grow slowly, since most demand is served by the existing installed base.
By type, the microarray analysis market is segmented into DNA microarrays (genotyping, copy number & cytogenetic, methylation, and expression arrays), protein & antibody microarrays, tissue & cell microarrays, and other microarrays such as carbohydrate arrays. In 2026, DNA microarrays are expected to hold the largest share and also to grow at the highest CAGR, as most remaining demand comes from cohort, farm, and drug-response genotyping and from copy number testing, the uses where arrays keep either a clear cost advantage or a reimbursed clinical role. Protein & antibody microarrays should grow modestly on autoantibody profiling, biomarker screening, and immune response work, while facing competition from multiplexed bead-based and proximity-based proteomic platforms. Tissue & cell microarrays are expected to grow slowly, keeping a role in pathology research and antibody validation as spatial profiling methods take on questions tissue arrays cannot answer.
By application, the microarray analysis market is segmented into genotyping (population & biobank, pharmacogenomic, and polygenic risk), cytogenetics & copy number analysis (CNV), gene expression profiling, agrigenomics & animal breeding, proteomic & biomarker profiling, and other applications. In 2026, genotyping is expected to hold the largest share and also to grow at the highest CAGR, supported by the economics of array genotyping with imputation in large cohorts, the launch of national cohort programs outside established markets, and the fit of arrays with pharmacogenomic and polygenic uses. Cytogenetics & copy number analysis should keep a large, steady share, as payers continue to cover chromosomal microarray testing for prenatal and pediatric cases. Agrigenomics should grow steadily, while gene expression profiling is expected to decline as RNA sequencing continues to replace expression arrays.
By end user, the microarray analysis market is segmented into academic & research institutes, biobanks & population genomics programs, clinical & diagnostic laboratories, agricultural & animal breeding organizations, and pharma & biotech companies. Clinical & diagnostic laboratories are expected to hold the largest share in 2026, given the high volume of chromosomal microarray tests in prenatal, pediatric, and cancer genetics, payer reimbursement for these tests, and the validated array platforms already in place in cytogenetics labs. Biobanks & population genomics programs are expected to grow at the highest CAGR, as established programs keep recruiting and genotyping participants, new national programs are starting in Asia-Pacific and the Middle East, and array genotyping with imputation remains far cheaper at this scale.
Regional Analysis
The report covers North America, Europe, Asia-Pacific, the Middle East & Africa, and Latin America, spanning 17 countries, the Nordic countries, and four rest-of-region groups. The regional analysis of the microarray analysis market considers clinical cytogenetics volumes and coverage policies, population genomics programs, agricultural genotyping, research activity, and the presence of array suppliers.In 2026, North America is expected to hold the largest share of the microarray analysis market, supported by the volume of chromosomal microarray analysis performed under established coverage policies, large-scale genotyping in dairy, beef, swine, and poultry breeding, strong research activity, and the home base of leading suppliers Illumina, Thermo Fisher Scientific, and Agilent Technologies. Europe holds a significant share, backed by large biobank and cohort programs that genotype at scale, established clinical cytogenetics services, and breeding organizations using genomic selection. With programs such as the U.K.'s Our Future Health, the region is among the heaviest users of population arrays relative to its size.
Asia-Pacific is expected to grow at the highest CAGR during the forecast period, driven by national genomics initiatives across China, Japan, India, and Southeast Asia where arrays are the cost-effective choice at that scale, growing livestock and crop genotyping as farm production intensifies, rising clinical cytogenetics capacity, and the arrival of array content designed for non-European ancestries. Latin America and the Middle East & Africa hold smaller shares. Latin American demand comes mainly from cattle and poultry genotyping in Brazil and Argentina, while in the Middle East, national genome programs and clinical genetics capacity in Gulf countries, where consanguinity-related conditions are common, are expected to support growth.
Competitive Landscape
The report provides a detailed review of the competitive landscape, covering key growth strategies, competitive benchmarking, the competitive dashboard (market leaders, market differentiators, vanguards, and emerging players), and market share/rank analysis by key player for 2025. Company profiles include business and financial overviews, microarray and product portfolios, strategic developments, and SWOT analyses.The microarray analysis market is concentrated, with two suppliers, Illumina and Thermo Fisher Scientific, providing most genotyping and expression array capacity, and the rest of the market split among cytogenetics array suppliers such as Agilent Technologies, protein and tissue array specialists such as RayBiotech and Sengenics, and genotyping service providers such as Eurofins Scientific. For the largest players, arrays are now a minor business next to much larger sequencing operations. Key purchase factors are cost per sample, content and ancestry coverage, data quality, and imputation support. Most activity centers on content instead of new platforms, such as arrays for multi-ancestry cohorts, drug-response and polygenic panels, and additional farm species. According to Neogen, which announced the deal in March 2026, it is selling its GeneSeek genomics business, including the Igenity and GGP livestock genotyping portfolios, to Zoetis for USD 160 million.
Key companies profiled in the report include Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Revvity, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Zoetis Inc. (GeneSeek) (U.S.), Eurofins Scientific SE (Luxembourg), RayBiotech Life, Inc. (U.S.), Sengenics Corporation LLC (Singapore), and Merck KGaA (Germany).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global microarray analysis market.
- Explains which applications still favor arrays over sequencing, and why, across population genotyping, agrigenomics, cytogenetics, and pharmacogenomics.
- Assesses the impact of sequencing displacement, low-pass whole-genome sequencing, payer policy changes, and supplier consolidation.
- Identifies growth opportunities across product, type, application, end user, and region in a mature market.
- Compares microarrays and next-generation sequencing on cost per sample and capability by application.
- Benchmarks leading suppliers on array portfolios, content development, services, and strategic developments.
- Supports portfolio planning, content investment, partnering, and market entry decisions for array suppliers, service providers, laboratories, and investors.
Key Questions Answered
- How big is the global microarray analysis market today, and how will it grow through 2036?
- Why is the market growing slowly, and which applications will sustain array demand?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- Why do biobanks and national cohort programs continue to genotype with arrays instead of sequencing?
- How could low-pass whole-genome sequencing affect array genotyping?
- How do payer coverage policies support chromosomal microarray analysis in prenatal and pediatric testing?
- Which products, types, applications, and end users will grow the fastest?
- Which regions and countries offer the most attractive business opportunities?
- Who are the leading suppliers, and how are they positioning their array portfolios against sequencing?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Insights
5. Microarray Analysis Market Assessment, by Product
6. Microarray Analysis Market Assessment, by Type
7. Microarray Analysis Market Assessment, by Application
8. Microarray Analysis Market Assessment, by End User
9. Microarray Analysis Market Assessment, by Geography
10. Competition Analysis
11. Company Profiles
12. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- Agilent Technologies, Inc.
- Revvity, Inc.
- Bio-Rad Laboratories, Inc.
- Zoetis Inc.
- Eurofins Scientific SE
- RayBiotech Life, Inc.
- Sengenics Corporation LLC
- Merck KGaA
